We came across a bullish thesis on Exelixis, Inc. on Investing With Purpose’s. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.'s share was trading at $37.42 as of August 29th. EXEL’s trailing and forward P/E were 17.99 and 17.33 respectively according to Yahoo Finance.
[caption id="attachment_575381" align="aligncenter" width="750"]Exelixis (EXEL) is a rare oncology biotech that combines profitability with growth optionality, driven by its flagship CABOMETYX franchise. CABOMETYX, approved across kidney, liver,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.